{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:36:25Z","timestamp":1791941785229,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s12325-009-0064-z","type":"journal-article","created":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T16:42:31Z","timestamp":1253378551000},"page":"813-825","source":"Crossref","is-referenced-by-count":99,"title":["Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension"],"prefix":"10.1007","volume":"26","author":[{"given":"David","family":"Montani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Camille","family":"Chaumais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Natali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ja\u00efs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,19]]},"reference":[{"key":"64_CR1","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G. Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43\u2013S54.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"G.E. D\u2019Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343\u2013349.","journal-title":"Ann Intern Med"},{"key":"64_CR3","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","volume":"54","author":"P.M. Hassoun","year":"2009","unstructured":"Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54:S10\u2013S19.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR4","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","volume":"54","author":"N.W. Morrell","year":"2009","unstructured":"Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20\u2013S31.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","volume":"172","author":"J. Wharton","year":"2005","unstructured":"Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105\u2013113.","journal-title":"Am J Respir Crit Care Med"},{"key":"64_CR6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","volume":"334","author":"J.D. Corbin","year":"2005","unstructured":"Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930\u2013938.","journal-title":"Biochem Biophys Res Commun"},{"key":"64_CR7","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","volume":"329","author":"S. Moncada","year":"1993","unstructured":"Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002\u20132012.","journal-title":"N Engl J Med"},{"key":"64_CR8","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","volume":"105","author":"E. Michelakis","year":"2002","unstructured":"Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398\u20132403.","journal-title":"Circulation"},{"key":"64_CR9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00395-004-0504-5","volume":"100","author":"B. Tantini","year":"2005","unstructured":"Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100:131\u2013138.","journal-title":"Basic Res Cardiol"},{"key":"64_CR10","doi-asserted-by":"crossref","first-page":"L536","DOI":"10.1152\/ajpcell.1994.266.2.C536","volume":"266","author":"K.F. Rabe","year":"1994","unstructured":"Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536\u2013L543.","journal-title":"Am J Physiol"},{"key":"64_CR11","first-page":"1527","volume":"16","author":"D. Giordano","year":"2001","unstructured":"Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta. 2001;16:1527\u20131539.","journal-title":"Biochim Biophys Acta"},{"key":"64_CR12","first-page":"L931","volume":"275","author":"K.A. Hanson","year":"1998","unstructured":"Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol. 1998;275:L931\u2013L941.","journal-title":"Am J Physiol"},{"key":"64_CR13","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A. Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732\u20131739.","journal-title":"N Engl J Med"},{"key":"64_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.06-0682","volume":"131","author":"D. Montani","year":"2007","unstructured":"Montani D, Souza R, Binkert C, et al. Endothelin-1\/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest. 2007;131:101\u2013108.","journal-title":"Chest"},{"key":"64_CR15","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","volume":"54","author":"R.J. Barst","year":"2009","unstructured":"Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S78\u2013S84.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR16","doi-asserted-by":"crossref","first-page":"208S","DOI":"10.1378\/chest.114.3_Supplement.208S","volume":"114","author":"A. Giaid","year":"1998","unstructured":"Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest. 1998;114:208S\u2013212S.","journal-title":"Chest"},{"key":"64_CR17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A. Giaid","year":"1995","unstructured":"Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214\u2013221.","journal-title":"N Engl J Med"},{"key":"64_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.158.4.9802113","volume":"158","author":"S.L. Archer","year":"1998","unstructured":"Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1061\u20131067.","journal-title":"Am J Respir Crit Care Med"},{"key":"64_CR19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","volume":"5","author":"H.A. Ghofrani","year":"2006","unstructured":"Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689\u2013702.","journal-title":"Nat Rev Drug Discov"},{"key":"64_CR20","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1046\/j.1432-1327.2001.02233.x","volume":"268","author":"V.K. Gopal","year":"2001","unstructured":"Gopal VK, Francis SH, Corbin JD. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem. 2001;268:3304\u20133312.","journal-title":"Eur J Biochem"},{"key":"64_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1164\/rccm.200302-282OC","volume":"169","author":"R.T. Schermuly","year":"2004","unstructured":"Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39\u201345.","journal-title":"Am J Respir Crit Care Med"},{"key":"64_CR22","first-page":"1488","volume":"44","author":"H.A. Ghofrani","year":"2004","unstructured":"Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44:1488\u20131496.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1742-1241.2006.01049.x","volume":"60","author":"P.J. Wright","year":"2006","unstructured":"Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006;60:967\u2013975.","journal-title":"Int J Clin Pract"},{"key":"64_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","volume":"64","author":"G. Burgess","year":"2008","unstructured":"Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64:43\u201350.","journal-title":"Eur J Clin Pharmacol"},{"key":"64_CR25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","volume":"48","author":"R.E. Wrishko","year":"2008","unstructured":"Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008;48:610\u2013618.","journal-title":"J Clin Pharmacol"},{"key":"64_CR26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","volume":"30","author":"M. Humbert","year":"2007","unstructured":"Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European postmarketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338\u2013344.","journal-title":"Eur Respir J"},{"key":"64_CR27","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N. Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148\u20132157.","journal-title":"N Engl J Med"},{"key":"64_CR28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","volume":"149","author":"G. Simonneau","year":"2008","unstructured":"Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521\u2013530.","journal-title":"Ann Intern Med"},{"key":"64_CR29","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N. Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894\u20132903.","journal-title":"Circulation"},{"key":"64_CR30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","volume":"95","author":"Z.C. Jing","year":"2009","unstructured":"Jing ZC, Jiang X, Wu BX, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart. 2009;95:1531\u20131536.","journal-title":"Heart"},{"key":"64_CR31","first-page":"515","volume":"73","author":"A.C. Guimaraes","year":"1999","unstructured":"Guimaraes AC, Malachias MV, Coelho OR, Zilli EC, Luna RL. Use of sildenafil in patients with cardiovascular disease. Arq Bras Cardiol. 1999;73:515\u2013526.","journal-title":"Arq Bras Cardiol"},{"key":"64_CR32","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/CIRCULATIONAHA.106.676809","volume":"115","author":"R.T. Schermuly","year":"2007","unstructured":"Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007;115:2331\u20132339.","journal-title":"Circulation"},{"key":"64_CR33","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M. Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425\u20131436.","journal-title":"N Engl J Med"},{"key":"64_CR34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/eurheartj\/ehn597","volume":"30","author":"E. Bedard","year":"2009","unstructured":"Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2009;30:256\u2013265.","journal-title":"Eur Heart J"},{"key":"64_CR35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/bja\/aem180","volume":"99","author":"L.C. Price","year":"2007","unstructured":"Price LC, Forrest P, Sodhi V, et al. Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth. 2007;99:552\u2013555.","journal-title":"Br J Anaesth"},{"key":"64_CR36","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/01.AOG.0000125148.82698.65","volume":"103","author":"H.J. Lacassie","year":"2004","unstructured":"Lacassie HJ, Germain AM, Valdes G, Fernandez MS, Allamand F, Lopez H. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol. 2004;103:1118\u20131120.","journal-title":"Obstet Gynecol"},{"key":"64_CR37","first-page":"87","volume":"98","author":"V. Molelekwa","year":"2005","unstructured":"Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K. Eisenmenger\u2019s syndrome in a 27 week pregnancy - management with bosentan and sildenafil. Ir Med J. 2005;98:87\u201388.","journal-title":"Ir Med J"},{"key":"64_CR38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/cvr\/cvp002","volume":"82","author":"S. Schafer","year":"2009","unstructured":"Schafer S, Ellinghaus P, Janssen W, et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res. 2009;82:30\u201339.","journal-title":"Cardiovasc Res"},{"key":"64_CR39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/78.10.1207","volume":"78","author":"S. Bhatia","year":"2003","unstructured":"Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc. 2003;78:1207\u20131213.","journal-title":"Mayo Clin Proc"},{"key":"64_CR40","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","volume":"108","author":"E.D. Michelakis","year":"2003","unstructured":"Michelakis ED, Tymchak W, Noga M, et al. Longterm treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066\u20132069.","journal-title":"Circulation"},{"key":"64_CR41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200210-1157BC","volume":"167","author":"H.A. Ghofrani","year":"2003","unstructured":"Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003;167:1139\u20131141.","journal-title":"Am J Respir Crit Care Med"},{"key":"64_CR42","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","volume":"43","author":"B.K. Sastry","year":"2004","unstructured":"Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149\u20131153.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ahj.2005.09.006","volume":"151","author":"T.P. Singh","year":"2006","unstructured":"Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.","journal-title":"Am Heart J"},{"key":"64_CR44","first-page":"2417","volume":"34","author":"D.B. Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34:2417\u20132422.","journal-title":"J Rheumatol"},{"key":"64_CR45","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","volume":"171","author":"M.R. Wilkins","year":"2005","unstructured":"Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292\u20131297.","journal-title":"Am J Respir Crit Care Med"},{"key":"64_CR46","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","volume":"24","author":"M.M. Hoeper","year":"2004","unstructured":"Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24:1007\u20131010.","journal-title":"Eur Respir J"},{"key":"64_CR47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","volume":"42","author":"H.A. Ghofrani","year":"2003","unstructured":"Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158\u2013164.","journal-title":"J Am Coll Cardiol"},{"key":"64_CR48","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.105.603001","volume":"114","author":"S. Mukhopadhyay","year":"2006","unstructured":"Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006;114:1807\u20131810.","journal-title":"Circulation"},{"key":"64_CR49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1291\/hypres.29.123","volume":"29","author":"K. Aizawa","year":"2006","unstructured":"Aizawa K, Hanaoka T, Kasai H, et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res. 2006;29:123\u2013128.","journal-title":"Hypertens Res"},{"key":"64_CR50","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MD.0b013e31818193bb","volume":"87","author":"D. Montani","year":"2008","unstructured":"Montani D, Achouh L, Dorfmuller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87:220\u2013233.","journal-title":"Medicine (Baltimore)"},{"key":"64_CR51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/09031936.00090608","volume":"33","author":"D. Montani","year":"2009","unstructured":"Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2009;33:189\u2013200.","journal-title":"Eur Respir J"},{"key":"64_CR52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1590\/S0100-879X2005000200006","volume":"38","author":"A.C. Barreto","year":"2005","unstructured":"Barreto AC, Franchi SM, Castro CR, Lopes AA. Oneyear follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res. 2005;38:185\u2013195.","journal-title":"Braz J Med Biol Res"},{"key":"64_CR53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/thx.2007.088831","volume":"63","author":"B.C. Creagh-Brown","year":"2008","unstructured":"Creagh-Brown BC, Nicholson AG, Showkathali R, Gibbs JS, Howard LS. Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. Thorax. 2008;63:933\u2013934.","journal-title":"Thorax"},{"key":"64_CR54","doi-asserted-by":"crossref","unstructured":"Montani D, Jais X, Price LC, et al. Cautious use of epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J. 2009. DOI: 10.1183\/09031936.00017809.","DOI":"10.1183\/09031936.00017809"},{"key":"64_CR55","doi-asserted-by":"crossref","unstructured":"Montani D, Ja\u00efs X, Dorfm\u00fcller P, Simonneau G, Sitbon O, Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J. 2009. DOI: 10.1183\/09031936.00102609.","DOI":"10.1183\/09031936.00102609"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-009-0064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-009-0064-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-009-0064-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:55:56Z","timestamp":1559447756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-009-0064-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1007\/s12325-009-0064-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}